GSK3B and cancer: In summary, the major findings in this study can be illustrated in Figure 8: (1) For the first time, we have confirmed that xanthatin independently downregulate GSK3β and STAT3 activities, which were both essential for the anticancer effect on NSCLC; (2) Dominant STAT3 inhibition contributes to minimize the risk of the canonical Wnt pathway in response to inactive GSK3β, which offers a new perspective on the ability to inhibit more than one pathway interpreted by xanthatin in cancer treatment.